Furthermore, treatment of RA-ILD fibroblasts with SDC2 decreases the levels of phosphorylated Akt and PAD2 and attenuates myofibroblast differentiation and extracellular matrix gene expression. The gene discussed is AKT1; the disease is rheumatoid arthritis.